Transgender Cancer Screening
Maya Leiva, PharmD, BCOP joins the Pod for Pride to give an overview of cancer screenings in the transgender population.
Jun 02, 2022•21 min
OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
What's Next In NSCLC & AML?
Looking at some interesting articles as possible predictors of what to expect next in NSCLC and AML. NADIM: https://pubmed.ncbi.nlm.nih.gov/?term=35576508 Ven + Intensive Chemo: https://doi.org/10.1016/S2352-3026(22)00100-4
May 26, 2022•16 min
How To Use Our Favorite Guidelines
By listener request, we discuss how to utilize our favorite guidelines.
May 19, 2022•21 min
Docetaxel
A Foundation of OncoPharm: Docetaxel
May 12, 2022•14 min
Adjuvant HD Cisplatin-RT For High Risk Head & Neck Cancer
The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer. Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274 EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646
May 05, 2022•17 min
Melanoma In A Nutshell
The highlights, and only the highlights, of melanoma.
Apr 28, 2022•11 min
Loong TFRs In CML, A Lack Of Agility, & CHEKCMATE 816
Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).
Apr 21, 2022•22 min
Ribociclib-Tamoxifen: A Cautionary Tale
Ribociclib-Tamoxifen: A Cautionary Tale by John Bossaer
Apr 14, 2022•11 min
Relatlimab + Nivo And the VISION trial
Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.
Apr 07, 2022•18 min
HOPA Boston Preview
Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston. Also, great educational programming awaits!
Mar 28, 2022•17 min
DESTINY-Breast03
Trastuzumab deruxtecan vs. trastuzumab trastuzumab
Mar 24, 2022•16 min
Chemo Toxicity Prediction & Risk
We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377
Mar 17, 2022•15 min
Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)
Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.
Mar 10, 2022•17 min
7 + 3
The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3" 7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203
Mar 03, 2022•12 min
Prostate Ca Updates From ASCO GU 22
We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.
Feb 24, 2022•19 min
Bacillus Calmette-Guerin
Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/
Feb 17, 2022•18 min
KIR, HLA - C, & Rituximab
This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00...
Feb 10, 2022•22 min
GI Cancer Updates & Tebentafusp
We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?
Feb 03, 2022•22 min
Precision Medicine Demystified
Dr. Howard McLeod joins the pod to talk Precision Medicine and the role pharmacists can play using pharmacogenomics and tumor genomics in cancer care. https://www.drhowardmcleod.com
Jan 27, 2022•57 min
New Hallmarks Of Cancers & LenPembro For Endometrial Cancer
Topic covered include the latest updates to the seminal Hallmarks of Cancer work, adjuvant pembrolizumab for stage IIB/IIC melanoma, a prospective study of UGT1A1 testing, and Keynote-775. Hallmarks of Cancer: New Dimensions. https://cancerdiscovery.aacrjournals.org/content/12/1/31 UGT1A1 Genotype-guided dosing of irinotecan: https://doi.org/10.1016/j.ejca.2021.12.009 Keynote-775: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330
Jan 20, 2022•19 min
Carfilzomib
Foundations of OncoPharm: Carfilzomib (and a fair bit of bortezomib)
Jan 13, 2022•27 min
So, You Want to Work (from home) as a Specialty Pharmacist
We're joined by Dr. Ryan McDade to hear about working as a Clinical Pharmacy Lead for Humana Specialty Pharmacy.
Jan 06, 2022•21 min
Drugs of 2021: Keep, Return Or Re-gift?
Happy Holidays!
Dec 23, 2021•10 min
ASH21 The More Things Change...
Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.
Dec 16, 2021•28 min
So, You Want to be a Pediatric Oncology Pharmacist
The 2nd episode in our Career Paths series features Dr. Morgan Randolph. She gives great insight into her role as pediatric oncology pharmacist and the choice between a PGY2 in Pediatrics or Oncology for those considering that decision.
Dec 09, 2021•21 min
Dasatinib Dosing & DREAMseq
Lots of updates to discuss from dasatinib dosing to ICI/TKI sequencing in BRAF-mutated metastatic melanoma to adjuvant chemo in node (+) breast cancer to some FDA approval updates.
Dec 02, 2021•20 min
Sun's Out, T Cells Out
Discussing one of the more intriguing studies of the year looking at whether metastatic melanoma survival is effected by what time of day immunotherapy is administered. Link: https://doi.org/10.1016/S1470-2045(21)00546-5
Nov 18, 2021•14 min
So, You Want To Be An MSL Oncology Pharmacist
What is a medical science liaison (MSL) and what do they do? Our 1st episode in a series highlighting different career options for oncology pharmacists featuring Dr. Christan Thomas.
Nov 11, 2021•23 min
Asciminib
Asciminib is now FDA approved and it's not just another TKI for CML
Nov 04, 2021•19 min
Adjuvant Atezo, Palbo-PPI Interaction? And More
From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode. Adjuvant atezolizumab for select NSCLC patients now FDA approved. 5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3 CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1 Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231
Oct 28, 2021•20 min
For the best experience, listen in Metacast app for iOS or Android